ImmunityBio (IBRX) EPS (Basic) Growth (1y) (2015 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) EPS (Basic) Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -16.29% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | ImmunityBio | 8.51 Bn | 8.15 Bn | 50.94 Mn | -110.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -110.44% |
| Mar 31, 2026 | -305.46% |
| Dec 31, 2025 | 20.63% |
| Sep 30, 2025 | 42.33% |
| Jun 30, 2025 | 46.78% |
| Mar 31, 2025 | 23.76% |
| Dec 31, 2024 | 81.51% |
| Sep 30, 2024 | 35.79% |
| Jun 30, 2024 | 37.99% |
| Mar 31, 2024 | 26.75% |
| Dec 31, 2023 | -69.41% |
| Sep 30, 2023 | 30.93% |
| Jun 30, 2023 | -32.59% |
| Mar 31, 2023 | -5.13% |
| Dec 31, 2022 | -15.16% |
| Sep 30, 2022 | -23.13% |
| Jun 30, 2022 | -2.59% |
| Mar 31, 2022 | -23.11% |
| Dec 31, 2021 | 64.48% |
| Sep 30, 2021 | 63.08% |